Effectiveness and safety of apixaban, LMWH, and warfarin among high-risk subgroups of VTE patients with active cancer
Alexander T. Cohen, Allison Keshishian, Theodore Lee, Lisa Rosenblatt, Patrick Hlavacek, Janvi Sah, Xuemei Luo
Abstract
OBJECTIVE: This pooled claims database study evaluated the risk of recurrent Venous Thromboembolism (VTE) and major bleeding (MB) among patients with VTE and active cancer prescribed apixaban, low-molecular weight heparin (LMWH), or warfarin stratified by high-risk subgroups. METHODS: < .10) of the interaction between treatment effects and subgroups was evaluated. RESULTS: = .002) for recurrent VTE. CONCLUSIONS: Across these high-risk subgroups of VTE cancer patients, treatment outcomes associated with apixaban were generally positive compared to LMWH and warfarin.
Topics & Concepts
MedicineApixabanWarfarinInternal medicineHazard ratioOncologySubgroup analysisCancerRivaroxabanMeta-analysisConfidence intervalAtrial fibrillationVenous Thromboembolism Diagnosis and ManagementAtrial Fibrillation Management and OutcomesLymphoma Diagnosis and Treatment